Mylan (NASDAQ:MYL) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Friday.

MYL has been the topic of a number of other research reports. Wells Fargo & Company set a $32.00 price objective on shares of Mylan and gave the stock a “hold” rating in a research note on Wednesday, October 4th. Morgan Stanley raised their price objective on shares of Mylan from $36.00 to $39.00 and gave the stock an “equal weight” rating in a research note on Friday, October 6th. Cantor Fitzgerald set a $34.00 price objective on shares of Mylan and gave the stock a “hold” rating in a research note on Wednesday, August 9th. BidaskClub raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Friday, October 27th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 price objective on shares of Mylan in a research note on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $41.49.

Mylan (NASDAQ:MYL) traded up $1.59 on Friday, reaching $38.12. 7,798,740 shares of the company’s stock were exchanged, compared to its average volume of 4,753,976. Mylan has a 12 month low of $29.39 and a 12 month high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The stock has a market cap of $19,596.02, a price-to-earnings ratio of 7.77, a PEG ratio of 2.00 and a beta of 1.39.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. equities research analysts anticipate that Mylan will post 4.56 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its stake in Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after purchasing an additional 1,475 shares during the last quarter. BT Investment Management Ltd acquired a new stake in Mylan during the 3rd quarter worth $142,000. Global X Management Co. LLC boosted its stake in Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after purchasing an additional 1,786 shares during the last quarter. Doliver Capital Advisors LP acquired a new stake in Mylan during the 2nd quarter worth $201,000. Finally, Eagle Global Advisors LLC acquired a new stake in Mylan during the 2nd quarter worth $205,000. 73.86% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/02/mylan-myl-stock-rating-upgraded-by-valuengine.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.